Verification evidence is still being completed.
PDF / print export
Heidelberg Pharma
Heidelberg, Germany
- Verified lead
- Dr. Dongzhou Jeffery Liu
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Antibody-Drug Conjugates, Amanitin Payloads, Targeted Oncology, and Bioconjugation
- Review cycle
- May 2026
- Full address
- Gregor-Mendel-Straße 22, 68526 Ladenburg, Germany
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Heidelberg Pharma management disclosure.
- Editorial note
- Clinical-stage ADC anchor with payload-linker know-how, oncology programme depth, and Heidelberg cluster connectivity.
Antibody-Drug Conjugates, Amanitin Payloads, Targeted Oncology, and Bioconjugation
Clinical-stage oncology quality systems, GxP development controls
Clinical-stage ADC anchor with payload-linker know-how, oncology programme depth, and Heidelberg cluster connectivity.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Company profile · Heidelberg, Germany
Heidelberg Pharma
Antibody-Drug Conjugates, Amanitin Payloads, Targeted Oncology, and Bioconjugation · Clinical-stage ADC platform
Verified 15 Mar 2026 · 3 sources
Clinical
Clinical-stage ADC anchor with payload-linker know-how, oncology programme depth, and Heidelberg cluster connectivity.
Contact & location
- Website
- heidelberg-pharma.com
- Company page
- Lead
- Dr. Dongzhou Jeffery Liu (verified ↗)
- Compliance
- GxP development controls
- Last reviewed
- 15 Mar 2026 (3mo ago)
- Scale
- Clinical-stage ADC platform
- Capabilities
- ADC discovery and development · Toxin-linker engineering · Preclinical oncology programmes
- Founded
- 1997
- Headcount
- 51-200
Clinical profileSTATUS: VERIFIED MARCH 2026
Dr. Dongzhou Jeffery Liu
Chief Executive Officer
Full addressGregor-Mendel-Straße 22, 68526 Ladenburg, Germany
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Heidelberg Pharma contact page naming Gregor-Mendel-Straße 22, Ladenburg as the registered office.
Open sourceClinical-stage ADC platform
Heidelberg, Germany. Antibody-Drug Conjugates, Amanitin Payloads, Targeted Oncology, and Bioconjugation. Review completed on 15 Mar 2026.
German biotech and clinical-development regulatory framework
Clinical-stage oncology quality systems, GxP development controls
Antibody-Drug Conjugates, Amanitin Payloads, Targeted Oncology, and Bioconjugation
Clinical-stage ADC anchor with payload-linker know-how, oncology programme depth, and Heidelberg cluster connectivity.
Related companies
Editorial note
Heidelberg Pharma is one of the Rhine-Neckar cluster's clearest oncology-platform anchors, with publicly disclosed management and a distinctive toxin-linker payload strategy from its Ladenburg site.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
ADC discovery and development
Toxin-linker engineering
Preclinical oncology programmes
Clinical-stage platform development
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
ADC discovery laboratories
Bioconjugation platform
Preclinical development infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- VERIFIED ACTIVE 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
15 Mar 2026: Executive identity confirmed via official management disclosure.
15 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Heidelberg Pharma located?
- Heidelberg Pharma operates from Gregor-Mendel-Straße 22, 68526 Ladenburg, Germany, Heidelberg, Germany.
- Who runs Heidelberg Pharma?
- Heidelberg Pharma is led by Dr. Dongzhou Jeffery Liu, Chief Executive Officer. Verified 15 Mar 2026.
- What certifications does Heidelberg Pharma hold?
- Heidelberg Pharma is documented under GxP development controls.
- What does Heidelberg Pharma do?
- Clinical-stage ADC anchor with payload-linker know-how, oncology programme depth, and Heidelberg cluster connectivity. Core capabilities: ADC discovery and development, Toxin-linker engineering, Preclinical oncology programmes, Clinical-stage platform development.
Editorial context
Related technical briefs
Briefs that name Heidelberg as a covered market or city.